Eli Lilly is rapidly ascending the ranks of the stock market, fueled by its groundbreaking diabetes and weight loss treatments, and is on track to potentially join the prestigious $1 trillion market capitalization club. Currently, only ten companies, including tech giants like Nvidia, Apple, and Microsoft, boast such a valuation on U.S. exchanges.
The pharmaceutical giant has gained significant attention for its innovative medications, particularly Mounjaro, a treatment for type 2 diabetes, and Zepbound, which targets weight management. These products have shown remarkable growth, with Mounjaro sales skyrocketing from $3.1 billion last year to $6.5 billion in the third quarter, while Zepbound generated $3.58 billion, up from $2.3 billion. This surge is significant, considering that obesity affects 43.1% of adults in the U.S. Furthermore, the global anti-obesity drug market is projected to balloon from $6.6 billion in 2023 to a staggering $77.24 billion by 2030, reflecting an explosive compound annual growth rate of 31.66%.
In addition to these key products, Eli Lilly is diversifying its portfolio with other successful treatments. Jaypirca, a drug for leukemia and small lymphocytic lymphoma, saw a tremendous 61% increase in prescriptions, contributing $143 million to the company’s third-quarter revenue. Sales from Ebglyss, which treats eczema, rose to $127 million, while the cancer drug Verzenio generated $1.4 billion in sales, marking a 7% year-over-year increase.
The impressive performance of Mounjaro and Zepbound is pivotal for Eli Lilly, accounting for $10.1 billion of the company’s total third-quarter revenue of $17.6 billion. This strong showing contributed to a 54% increase in overall revenue compared to the previous year, with earnings per share soaring from $1.07 to $6.21.
As of now, Eli Lilly has a market capitalization of $969 billion and its stock price is up 30% this year alone. To reach the coveted $1 trillion mark, the company only needs an 11% boost in its stock price. Over the past 12 months, Eli Lilly reported revenues of $59.42 billion and is projected to reach $75.3 billion in the coming year, representing a robust 26% growth. With a forward price-to-sales ratio of 14.1, if the company meets its revenue targets, its market cap could exceed $1 trillion by 2026.
Looking ahead, Eli Lilly is strategically positioning itself to leverage its success in the diabetes and weight loss sectors. The company is expanding its manufacturing capabilities by investing billions in new drug production facilities in Virginia and Texas while also upgrading a site in Puerto Rico. Additionally, a partnership with Nvidia for artificial intelligence could revolutionize its drug discovery processes.
With an extensive pipeline of potential medications for various conditions, including ulcerative colitis, Alzheimer’s disease, and additional cancer therapies, Eli Lilly is poised for both consistent profits and significant growth. Its unique position in the weight loss and diabetes markets amplifies its momentum, suggesting a solid trajectory toward achieving a $1 trillion valuation in the near future.
